Search for Clinical Trial Results
Lymphoma, Large-Cell, Anaplastic - 25 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) Condition:
Date: 2012-08-02 Interventions:
|
Completed |
Study Name: Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma Condition:
Date: 2008-01-21 Interventions: Biological: XmAb2513 Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, |
Active, not recruiting |
Study Name: Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Condition:
|
Withdrawn |
Study Name: Denileukine Diftitox for Relapsed ALCL Condition: Anaplastic Large-Cell Lymphoma Date: 2008-12-03 Interventions:
|
Recruiting |
Study Name: Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL Condition: ALK+ Anaplastic Large Cell Lymphoma Date: 2015-05-18 Interventions:
|
Recruiting |
Study Name: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Condition:
|
Suspended |
Study Name: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Condition:
|
Completed |
Study Name: 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Condition:
|
Recruiting |
Study Name: Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + Condition: ALCL Date: 2016-09-07 Interventions: Other: Blood sample |
Completed |
Study Name: Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma Condition: Lymphoma Date: 2011-06-02 Interventions:
|